# INVO Fertility, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/INVO Fertility, Inc.). ## Overview INVO Fertility, Inc. is a U.S.-based fertility care company that has shifted from primarily distributing its INVOcell medical device to operating fertility clinics and acquiring IVF practices. Its model combines clinic-based assisted reproductive technology services with continued sales of INVOcell to third-party clinics, with a stated focus on underserved secondary markets. ## Products & services • INVOcell intravaginal culture device and IVC procedure • Fertility clinic services through INVO Centers • IVF clinic operations and acquisitions • IUI and broader ART care offerings • Direct distribution of INVOcell to third-party clinics - **Fertility clinic services** (85%) — Clinic-based ART services including INVO Centers, IVF, IVC and IUI treatments. - **IVF clinic operations** (10%) — Revenue from acquired profitable IVF clinics, including the Wisconsin Fertility Institute. - **INVOcell device sales** (5%) — Direct sale and distribution of the INVOcell device to third-party fertility clinics. - INVOcell device for intravaginal culture (IVC) - INVO Centers offering fertility clinic services - Acquired and operated IVF clinics - IUI and other assisted reproductive technology services - Direct sales/distribution of INVOcell to clinics ## Customers The company serves fertility patients seeking assisted reproductive technology, especially in markets where traditional IVF access is limited or costly. Its direct buyers also include fertility clinics that purchase INVOcell to offer IVC as an alternative treatment pathway. - **Fertility patients** (primary) — Patients purchasing clinic-based ART services such as IVF, IVC and IUI, often seeking more affordable or accessible care. - **Third-party fertility clinics** (secondary) — Clinics that buy INVOcell to offer the IVC procedure and expand treatment options for their patients. - **Acquired IVF clinic patient base** (primary) — Patients served through owned IVF clinics such as Wisconsin Fertility Institute. - Infertility patients seeking lower-cost ART options - Patients in secondary markets with limited clinic capacity - Couples choosing IVF, IVC or IUI treatments - Third-party fertility clinics buying INVOcell devices - Clinics and physicians seeking differentiated fertility offerings ## Geography INVO Fertility’s current commercial footprint is concentrated in the United States, where its INVO Centers and acquired IVF clinic are located. The company says it has limited proactive international marketing for INVOcell after weaker traction abroad, while remaining open to foreign markets that can produce profitable incremental revenue. - **United States** (100%) — Current operations and commercial focus are primarily U.S.-based. - United States is the core market for clinics and device sales - Two operational INVO Centers are in the U.S. - One acquired IVF clinic is in the U.S. - International INVOcell marketing has been scaled back - Future expansion may target profitable foreign clinic partners ## Strategy The company is prioritizing clinic ownership and acquisition over pure device distribution, with the goal of building scale, improving cash flow and reaching profitability. It also plans to keep expanding INVOcell distribution where it can support profitable growth, while focusing on underserved secondary markets and operational efficiency. - **Acquire profitable IVF clinics** (short-term) — Adds immediate scale, positive cash flow and a larger patient base. - **Expand INVO Centers** (medium-term) — Builds a clinic network around the INVOcell-enabled IVC model and broadens access. - **Maintain selective INVOcell distribution** (medium-term) — Preserves a device revenue stream and supports adoption of the IVC procedure. - Expand owned fertility clinics and INVO Centers - Acquire profitable IVF clinics to add scale and cash flow - Use secondary markets to differentiate on access and pricing - Continue selective INVOcell distribution in the U.S. - Pursue profitability through operational efficiency ## Risks The business depends on successful clinic execution, patient volumes and integration of acquired practices, so operational missteps can quickly affect margins and cash flow. It also faces industry risks tied to reimbursement, competition from established IVF providers, and the challenge of proving that INVOcell and IVC can scale economically in a market dominated by conventional IVF. - **Clinic utilization and operational execution** [high] — Revenue is increasingly tied to owned clinics, so downtime, procedure mix or staffing issues can hurt results. - **Acquisition integration risk** [high] — Growth depends on acquiring profitable clinics and integrating them without disrupting operations. - **Fertility market reimbursement and pricing pressure** [medium] — Patient demand and clinic economics are sensitive to insurance coverage and out-of-pocket affordability. - **INVOcell adoption risk** [medium] — Device sales depend on third-party clinics choosing to offer IVC instead of standard IVF. - Clinic utilization risk if patient volumes do not ramp as planned - Acquisition integration risk from buying and operating IVF clinics - Reimbursement and pricing pressure in fertility care - Competitive risk from established IVF providers and local clinics - Device adoption risk if third-party clinics do not expand INVOcell use ## Accounting Investors should watch revenue recognition across two different models: clinic services and device sales, which may have different timing and margin profiles. The company also has meaningful judgment areas around consolidation of joint ventures and variable interest entities, acquisition accounting, and stock-based compensation, all of which can materially affect reported earnings and balance sheet values. - **Revenue recognition by business line** — Reported revenue mix and gross margin - **Consolidation of VIEs and joint ventures** — Balance sheet size and operating results - **Business acquisition accounting** — Non-cash charges and book value - **Stock-based compensation** — Operating expenses and net loss - Clinic service revenue and device sales may be recognized differently - Joint ventures and VIEs affect consolidation and reported results - Acquisition accounting can create goodwill and intangible assets - Stock-based compensation can materially affect operating expenses - Quarterly results may be distorted by downtime and procedure mix --- *Last updated: 2026-04-28T20:16:35.958586+00:00*